Previous studies suggest the safety of empiric anticoagulation administered to patients with suspected deep vein thrombosis (DVT) before the work-up is completed. However, the safety of such practice has not been thoroughly studied in the primary care setting.

To investigate the effects of the PI3 K inhibitor, linperlisib (YY20394), on proliferation, apoptosis, cell cycle and signaling pathways in acute myeloid leukemia (AML) cells.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to complications, depending on the period of the transplantation. Our study aimed to evaluate the outcome and prognostic parameters for the survival of patients admitted to the intensive care unit (ICU) in the post- or late-engraftment phase.

Early-onset multiple myeloma (MM), defined as being diagnosed before the age of 50, has become an increasing global concern. However, a systematic examination of the global epidemiological landscape of early-onset MM is still lacking.

Chronic myeloid leukemia in the chronic phase (CML-CP) has undergone therapeutic transformation with the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), improving 10-year survival rates from 20% to ∼90%. These outcomes place increasing importance on maintaining quality of life (QoL), which can be compromised by adverse events (AEs) that may lead to decreased adherence or sub-therapeutic doses. Currently, there is no standardized definition of treatment intolerance, and treatment switches are based on individual physician practices.

Acute myeloid leukemia (AML) is a genetic disorder caused by translocations or mutations that disrupt hematopoietic function and lead to malignant transformation. In recent years, microRNA-99a and miR-100 have been found to exhibit abnormal expression in solid tumors, but their roles in AML remain unclear. This study aims to investigate the expression levels of these two microRNAs in AML and their prognostic significance.

Aberrant Wnt signaling drives oncogenesis. DKK proteins, key extracellular regulators of Wnt pathway, play critical roles in tumor suppression or promotion.

Chromosome 7 abnormality characterized by loss of both arms [der(7)del(7p)del(7q), hereafter 'der(7)'] is very rare. The features and prognosis of patients with der(7) in myelodysplastic syndromes (MDS) remain unclear.

To clarify the association between active Epstein-Barr virus (EBV) infection and the risk of multiple myeloma (MM), given longstanding uncertainty regarding EBV's etiologic contribution to plasma cell malignancies.

Ewing sarcoma breakpoint region 1(EWSR1) rearrangements have been repeatedly observed in acute myeloid leukemia (AML). However, the clinical impact of EWSR1 expression is still unclear in AML. Therefore, we explored the prognostic significance of EWSR1 in AML.

Acute myeloid leukemia (AML) exhibits significant heterogeneity and aggressiveness. This study aimed to investigate T cell heterogeneity in the AML tumor microenvironment using single-cell RNA sequencing (scRNA-seq) and identify potential biomarkers for prognosis and precision therapy.

Peripheral T-cell lymphoma (PTCL) is characterized by significant heterogeneity and poor prognosis, with its high mortality rate remaining an unresolved challenge in clinical treatment. Recent studies have established metabolic syndrome (MetS) as a prognostic factor in various malignancies, yet its association with PTCL remains unexplored. This study aims to evaluate the impact of MetS on the prognosis of PTCL patients.

fusion has been identified in glioblastoma but has never been documented in hematologic malignancies. We document the first presentation of the fusion in a myelodysplastic syndrome (MDS) with rapid transition into secondary acute myeloid leukemia (sAML).

Autologous hematopoietic stem cell transplantation (auto-HSCT) is standard for eligible multiple myeloma (MM) patients, yet outcomes are heterogeneous. Besides established markers like cytogenetics and ISS, the independent prognostic value of pretreatment hemoglobin (Hb), myeloma subtype, and induction regimen requires clarification. This study aimed to assess these factors to improve risk stratification.

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet (PLT) destruction. Its clinical manifestations are highly heterogeneous, and the unclear pathogenesis poses significant challenges for effective treatment. The limited efficacy of current therapies underscores the need for novel therapeutic targets.

The combination of venetoclax and azacitidine shows significant efficacy in newly diagnosed acute myeloid leukemia (ndAML) patients. In specific contexts, low-dose venetoclax may be preferred to optimize patient tolerance.

Tyrosine kinase inhibitors (TKIs) have revolutionized the therapy of chronic myeloid leukemia (CML) in chronic phase, opening up the perspective of a normal life expectancy for most patients and of treatment-free remission for some of them. However, intolerance or resistance may necessitate treatment modifications.

Red cell distribution width (RDW) has been acknowledged for its prognostic importance in multiple myeloma (MM) patients. However, the connection between RDW and mortality rates among MM patients who are admitted to the Intensive Care Unit (ICU) is still not clear.

Bortezomib (BTZ) containing regimens induces significant antitumor response in multiple myeloma (MM) and are considered as the first-line treatment. However, resistance is still one of the unsolved problems. This study aims to explore the mechanism underlying BTZ resistance in MM.

To evaluate the safety and effectiveness of treatments for hemophilia in China through a literature review and evidence mapping, we systematically searched PubMed, Web of Science, Cochrane Library, CNKI, Wanfang, and CBM. Descriptive statistics were used for data analysis in this evidence mapping and the review concluded on 21 April 2025. Results were compiled in tabular or graphical form. This review included 49 studies (two RCTs and 47 observational studies), involving 2274 patients, 41 articles focusing on hemophilia A, seven on hemophilia B, and one on both. The average (mean or median) age of subjects within the individual studies ranged from 5.77 to 34.6 years. This study revealed a decrease in both annualized bleeding rate (ABR) and annualized joint bleeding rate (AJBR) following prophylaxis treatment and immune tolerance induction (ITI) treatment. The reduction in target joint count post-treatment aligns with previous research indicating successful hemostasis in most people with hemophilia after alternative therapies; long-term follow-up studies consistently showed improved imaging scores at various dosage levels, indicating disease amelioration. Additionally, our findings suggest enhanced quality of life for people with hemophilia following treatment. Alternative therapies, encompassing prophylaxis therapy, on-demand treatment, and ITI therapy, demonstrated both efficacy and safety in the management of hemophilia among Chinese people with hemophilia.

Myeloid sarcoma (MS) is a rare extramedullary manifestation of myeloid neoplasms and usually has poorer outcomes than acute myeloid leukemia without extramedullary disease. Allogeneic hematopoietic stem cell transplantation is the most effective consolidation, but evidence on allogeneic peripheral blood stem cell transplantation (allo-PBSCT), especially from haploidentical donors, is limited.